Given that the pathobiology of MS has presumably started before the prodromal phase, exploring biomarkers associated with neuronal injury and loss, such as neurofilament light chain (NfL), while not specific to MS, may be useful for the prodrome. The gene discussed is NEFL; the disease is myeloid sarcoma.